News Conference News ESC 2025 ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD L.A. McKeown September 09, 2025
News Conference News ESC 2025 ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation Todd Neale September 08, 2025
News Conference News ESC 2025 Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR Michael O'Riordan August 31, 2025
News Conference News ESC 2025 MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide Caitlin E. Cox August 30, 2025
News Conference News ESC 2025 Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support Todd Neale August 30, 2025
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News ESC 2023 Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST Michael O'Riordan August 27, 2023
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Conference News ESC 2022 Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR L.A. McKeown August 27, 2022
News Conference News ESC 2022 PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 Michael O'Riordan August 27, 2022
News Conference News ESC 2020 PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF Todd Neale August 30, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Conference News ESC 2019 Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis Yael L. Maxwell September 12, 2019
News Conference News ESC 2019 PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen Todd Neale September 01, 2019
News Conference News ESC 2018 Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND Michael O'Riordan August 26, 2018